Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | UBE2D3 | P61077 | 2/20 | 0.36 |
| ▸ | STS | P08842 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130957 | 0.91 | CA2 (0.41) | CA2ESR1UBE2D3STSCA1 | |
| SCHEMBL6130914 | 0.84 | CA2 (0.42) | CA2ESR1PTPN2PTPN1PTPN6 | |
| SCHEMBL6130971 | 0.82 | CA2 (0.58) | CA2ESR1STSCA1CA9 | |
| SCHEMBL6130909 | 0.76 | STS (0.48) | CA2ESR1STSCA1CA9 | |
| SCHEMBL6130940 | 0.75 | CA2 (0.43) | CA2ESR1STSCA1CA9 | |
| SCHEMBL6130945 | 0.73 | CA2 (0.57) | CA2ESR1STSCA1CA9 | |
| SCHEMBL6130968 | 0.69 | CA2 (0.61) | CA2ESR1STSCA1CA9 | |
| SCHEMBL6130920 | 0.68 | STS (0.42) | CA2ESR1PTPN2PTPN1PTPN6 | |
| SCHEMBL3866409 | 0.67 | CA2 (0.69) | CA2ESR1STSCA9 | |
| SCHEMBL3866395 | 0.67 | CA2 (0.77) | CA2ESR1STSCA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277625-A1 | Estriol and estetrol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-15 | — | — | US | claimed |
| US-20050277625-A1 | Estriol and estetrol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277625-A1 | Estriol and estetrol prodrugs | HSD17B11, CYP19A1, ESR1 | CA2 3004/4885ESR1 3/4885PTPN2 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.